Sign in to view content

Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials

Arshad M. Khanani, MD, MA, FASRS

Video
Published 2022

Related

Patients Ultra-Responsive to Ranibizumab (RBZ): Rates of Great Than or Equal to 4-Step Improvement in Diabetic Retinopathy Severity in DRCR.net Protocol S
Allen Chiang, MD, FASRS
Annual Meeting Talks
2019
Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: One-Year Primary Outcomes From the Randomized RECOVERY Trial
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2019
What Happens to Diabetic Retinopathy Severity Scores With Less Aggressive Treatment? A Post Hoc Analysis of the RISE and RIDE Open Label Extension Study
Roger A. Goldberg, MD, MBA
Annual Meeting Talks
2019

Category: wet AMD

See more